Exclusion criteria
bleeding, comorbidity, diarrhea, malignancy, carcinoma of the cervix, hypersensitivity, gastrointestinal disorders
BLEEDING, INFLAMMATION, CARCINOMA OF THE CERVIX, HYPERSENSITIVITY, GASTROINTESTINAL DISORDERS

Age < 18 yearsCNS metastasesActive, uncontrolled infectionAdditional malignancy within the past 2 years (except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer)Clinically significant gastrointestinal disorders including bleeding, inflammation, occlusion, or diarrhea > grade 1Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study resultsKnown hypersensitivity to FTD/TPI or Irinotecan or their componentsMedication that is known to interfere with any of the agents applied in the trialPregnancy or lactating femalePrior partial or total gastrectomyPrevious radio- or radiochemotherapy, previous transarterial chemoembolisation (TACE), radiofrequencyablation (RFA) or selective intraarterial radiotherapy (SIRT) within 3 months prior to inclusion (except radiation for bone metastases)Patients who might be dependent on the sponsor, site or the investigatorPatients who have been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].Use of other investigational treatment within 5 half-lives of enrollment is prohibited.